recent articles

FOAMED

Reversal of Anticoagulation in a True Emergency – An Update

Please see prior post here: http://www.emdocs.net/reversal-of-anticoagulation/ On October 16, 2015 the FDA granted accelerated approval of idarucizumab (Praxbind), a novel reversal agent of the direct thrombin inhibitor Dabigatran (Pradaxa), for utilization in life-threatening bleeding emergencies.1

practice updates

Reversal of Anticoagulation in a True Emergency

Nearly 65,000 patients visit U.S. emergency departments annually for anticoagulant related hemorrages.1 Despite this staggering amount, the aforementioned figure does not reflect adverse bleeding events associated with Direct Thrombin Inhibitors (DTIs) and Factor Xa Inhibitors. As EM Docs, it goes without saying that we need to know what to do to address these potentially life-threatening bleeds, so, let’s take a look at the commonly prescribed oral anticoagulants, their mechanisms of action, their pharmacokinetics, and recommendations for their reversal.